AskBio Knocks Down Enough Hurdles To Raise $235m For Its Gene Therapy Platform

While some companies rushed into gene therapy and exited after a single setback, Asklepios BioPharmaceutical quietly advanced its programs, identifying challenges and overcoming them one at a time. Now, it's ready to advance multiple programs into the clinic.